Colorectal Cancer — Expanded Access Programs
Overview
Right2Hope maintains a directory of 107 expanded access programs, clinical trials, and compassionate use pathways listed for Colorectal Cancer. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with colorectal cancer programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 38 programs are currently active or recruiting, with the remaining 69 in other lifecycle stages. Sponsors actively running programs in this area include M.D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), A2 Biotherapeutics Inc., Merus N.V., and others.
By recruiting status
Snapshot of where every Colorectal Cancer program currently sits in its lifecycle.
- Active / Recruiting38
- Draft1
- Inactive68
Top sponsors
Organisations running the most Colorectal Cancer programs in the directory.
- M.D. Anderson Cancer Center7 programs
- Memorial Sloan Kettering Cancer Center6 programs
- National Cancer Institute (NCI)6 programs
- A2 Biotherapeutics Inc.3 programs
- Merus N.V.3 programs
- Takeda3 programs
- AbbVie2 programs
- AstraZeneca2 programs
- Exelixis2 programs
- Merck Sharp & Dohme LLC2 programs
Colorectal Cancer programs (107)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on 177Lu-BetaBart for Patients with Advanced or Hard-to-Treat Solid Tumors — Radiopharm Theranostics, Ltd
- Study on VS-7375 for Patients with KRAS G12D-Mutated Solid Tumors — Verastem, Inc.
- Phase 2 Study of VS-7375 for Patients with KRAS G12D-Mutated Colorectal Cancer — Verastem, Inc.
- Phase 2 Study of Fruquintinib and Tislelizumab for Detecting Minimal Residual Disease in Colorectal Cancer After Chemotherapy — M.D. Anderson Cancer Center
- Study of Botensilimab and Balstilimab for Colorectal Cancer with ctDNA+ After Surgery and Chemotherapy — Memorial Sloan Kettering Cancer Center
- Study on Fruquintinib Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer — SCRI Development Innovations, LLC
- Study on PARG Inhibitor ETX-19477 for Patients with Advanced Solid Cancers — 858 Therapeutics, Inc.
- Study on IV Telisotuzumab Adizutecan with Bevacizumab vs. Standard Treatment for Advanced Colorectal Cancer — AbbVie
- Study on the Effects and Safety of Telisotuzumab Adizutecan for Colorectal Cancer Patients with Circulating Tumor DNA — AbbVie
- Study on the Safety and Effectiveness of A2B395 CAR T-Cell Therapy for Solid Tumors with Specific Genetic Markers — A2 Biotherapeutics Inc.
- Study on the Safety and Effectiveness of A2B530 CAR T-Cell Therapy for Solid Tumors with CEA Expression and HLA-A*02 Loss — A2 Biotherapeutics Inc.
- Study on the Safety and Effectiveness of Two Doses of ONO-4578 with Opdivo®, Combined with mFOLFOX6 and Bevacizumab, Compared to Standard Treatment for Advanced Colorectal Cancer — Ono Pharmaceutical Co. Ltd
- Study on ALE.P03 as a Single Treatment for Adults with Certain Advanced or Metastatic CLDN1+ Solid Tumors — Alentis Therapeutics AG
- Study on DSP107 and Atezolizumab Compared to Fruquintinib for Treating Colorectal Cancer — Kahr Bio Australia Pty Ltd
- Study on the Safety and Effects of Fruquintinib in Minority Patients with Advanced Colorectal Cancer — Takeda
- Study on Adding Antibiotics to Initial Treatment for Advanced Colorectal Cancer — Virginia Commonwealth University
- Study on NGM120 for Colorectal Cancer Patients with Cancer-Related Weight Loss — NGM Biopharmaceuticals, Inc
- Study on Entrectinib for Treating Solid Tumors with Specific Gene Changes — Hoffmann-La Roche
- Study on Botensilimab and Balstilimab for Colorectal Cancer — Nicholas DeVito, MD
- Study on Cabozantinib and Durvalumab, With or Without Tremelimumab, for Patients with Gastroesophageal and Other Gastrointestinal Cancers — Anwaar Saeed
- Study on Chemotherapy and Immunotherapy Combinations for Locally Advanced Rectal Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Dual Administration of TROP2-Directed CAR-NK Therapy for Colorectal Cancer Spread to the Abdomen — M.D. Anderson Cancer Center
- Study on Pembrolizumab/Quavonlimab Combination Versus Other Treatments for Advanced Colorectal Cancer with Specific Genetic Features — Merck Sharp & Dohme LLC
- Study on FOG-001 for Advanced or Metastatic Solid Tumors — Fog Pharmaceuticals, Inc.
- Study on Using Hepatic Arterial Infusion with Floxuridine and Dexamethasone Combined with Chemotherapy for Colorectal Cancer Spread to the Liver — Memorial Sloan Kettering Cancer Center
- Study on Post-Surgery Chemotherapy Treatments for Appendix, Colon, or Rectum Cancer with Peritoneal Spread — Memorial Sloan Kettering Cancer Center
- Study on Lead-212 PSV359 Therapy for Patients with Solid Tumors — Perspective Therapeutics
- Long-Term Study for Participants Continuing Treatment from a Previous Exelixis Study — Exelixis
- Study on LYL273 for Patients with Relapsed or Hard-to-Treat Metastatic Colorectal Cancer — Lyell Immunopharma, Inc.
- Phase 1/2 Study of S241656 for Cancers with Specific RAS/MAPK Mutations — Institut de Recherches Internationales Servier
- Study on Radiation and Chemotherapy, With or Without Additional Chemotherapy, Followed by Surgery for Stage II or III Rectal Cancer — Memorial Sloan Kettering Cancer Center
- Study on Regorafenib and Pembrolizumab for Treating Advanced or Metastatic Colorectal Cancer — University of Southern California
- Study of Cabozantinib and Nivolumab for Hard-to-Treat Metastatic Colorectal Cancer — University of Colorado, Denver
- Study on Dato-Dxd Alone and with Other Cancer Treatments for Advanced Solid Tumors (TROPION-PanTumor03) — AstraZeneca
- Study on Elironrasib and Daraxonrasib for Advanced KRAS G12C Mutant Solid Tumors — Revolution Medicines, Inc.
- Study Comparing XL092 and Atezolizumab with Regorafenib for Metastatic Colorectal Cancer — Exelixis
- Study on TAS-102 With or Without Celecoxib for Detecting Minimal Residual Disease in Colorectal Cancer After Chemotherapy — M.D. Anderson Cancer Center
- The Northern-European Initiative on Colorectal Cancer — Oslo University Hospital
- Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRAS — Providence Health & Services
- Study on [18F]FPyQCP PET Imaging for Detecting Certain Types of Cancer — Blue Earth Diagnostics
- Study on MK-2870 Alone or With Chemotherapy for Treating Gastrointestinal Cancers — Merck Sharp & Dohme LLC
- Study on CHM-2101 CAR T Cell Therapy for Advanced Gastrointestinal Cancers — Chimeric Therapeutics
- Study on TC-510 Cell Therapy for Advanced Cancers with Mesothelin Expression — TCR2 Therapeutics
- Phase 2 Study of Zanidatamab for Patients with HER2-positive Tumors — Jazz Pharmaceuticals
- Phase II Study on Using Immune Therapy to Preserve Organs in Colorectal or Gastroesophageal Cancer Patients — National Cancer Institute (NCI)
- Phase II Study of Immunotherapy for Advanced Gastrointestinal Cancers with KRAS or TP53 Mutations — National Cancer Institute (NCI)
- Phase IIa Study of Naproxen or Aspirin for Cancer Prevention in Lynch Syndrome — M.D. Anderson Cancer Center
- Study on FMC-376 for Patients with KRAS G12C Mutated Advanced Solid Tumors — Frontier Medicines Corporation
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors — Merus N.V.
- A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors — Kahr Medical
- Study on ELI-002 7P for Patients with KRAS/NRAS Mutated Solid Tumors — Elicio Therapeutics
- Study on IBI363 for Patients with Advanced Solid Tumors — Innovent Biologics (Suzhou) Co. Ltd.
- Study on LY2880070 for Patients with Advanced or Metastatic Cancer — Esperas Pharma Inc.
- Study on Navicixizumab Alone or Combined with Other Treatments for Advanced Solid Tumors — OncXerna Theraputics, Inc.
- Study on Oral Alintegimod with Ipilimumab and Nivolumab for Cancer Treatment — 7 Hills Pharma, LLC
- A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer — Memorial Sloan Kettering Cancer Center
- Study on TAK-186 (MVC-101) for Adults with Advanced or Metastatic Cancer — Takeda
- Study on Using Medtronic Pump and Codman Catheter for Chemotherapy in Patients with Colorectal or Bile Duct Cancer — Benaroya Research Institute
- Study on VS-6766 and Cetuximab for Patients with Advanced Colorectal Cancer — University of Chicago
- Study on IPN01194 for Adults with Advanced Solid Tumors — Ipsen
- Study on the Effects of CT3001 in Patients with Advanced Solid Tumors — Crossignal Therapeutics, Inc.
- Study on the Safety and Effectiveness of A2B694 CAR T-Cell Therapy for Solid Tumors with MSLN Expression and HLA-A*02 Loss — A2 Biotherapeutics Inc.
- Study on APL-5125 for Adults with Advanced Solid Tumors — Apollo Therapeutics Ltd
- Study on Using Tumor Infiltrating Lymphocytes for Treating Advanced Solid Cancers — Udai Kammula
- Study on BOLD-100 with FOLFOX for Treating Advanced Solid Tumors — Bold Therapeutics, Inc.
- Study on Cemiplimab With or Without Fianlimab for Treating Older Patients with Localized or Advanced MSI-H Colorectal Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Clinical Trial of All-trans-retinoic Acid, Bevacizumab, and Atezolizumab in Colorectal Cancer — University of Texas Southwestern Medical Center
- Comparing Two Chemotherapy Drugs Used During Surgery for Colorectal Cancer Spread to the Abdomen — University of Kansas Medical Center
- Study Comparing Different MRI Contrast Agents for Detecting Liver Cancer Spread — University of Colorado, Denver
- Early Access Program for HER2/HER3 Bispecific Antibody MCLA-128 for Patients with Advanced NRG1-Fusion Positive Solid Tumors — Merus N.V.
- Study on the Duration of PD-1/PD-L1 Inhibitor Treatment in Advanced Solid Tumors — Jason J. Luke, MD
- Study on Revumenib for Patients with Colorectal Cancer and Other Solid Tumors — Syndax Pharmaceuticals
- Access to TAK-113 for Adults with Advanced Colorectal Cancer — Takeda
- Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies — xCures
- Study on the Feasibility of Using the LUM Imaging System to Detect Gastrointestinal Cancers — Lumicell, Inc.
- Study on Using a Hepatic Artery Infusion Pump with Chemotherapy for Colorectal Cancer Spread to the Liver — National Cancer Institute (NCI)
- Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory — Northwestern University
- Study on Combining Immunotherapy and Radiation for Treating Metastatic Colorectal Cancer — National Cancer Institute (NCI)
- Study on Intravenous T3011 Alone and with Other Treatments for Advanced Solid Tumors — ImmVira Pharma Co. Ltd
- Study on LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab for Advanced or Metastatic Solid Tumors — PureTech
- Study on M9241 with Liver-Directed Chemotherapy and Systemic Therapy for Patients with Liver Metastases from Colorectal Cancer or Bile Duct Cancer — National Cancer Institute (NCI)
- Study on MCLA-129 Antibody Treatment for Advanced Lung and Other Solid Tumors — Merus N.V.
- Phase 2 Study of DKN-01 for Treating Colorectal Cancer — Leap Therapeutics, Inc.
- Phase I Study of Personalized T Cell Therapy for Advanced or Metastatic Solid Tumors with KRAS G12V Mutation — Affini-T Therapeutics, Inc.
- Study on Regorafenib and Lorigerlimab Before Surgery for Lung-Limited Metastatic Colorectal Cancer — M.D. Anderson Cancer Center
- Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases — Weill Medical College of Cornell University
- Study on JDQ443 Combination Therapy for Advanced Solid Tumors with KRAS G12C Mutation — Novartis Pharmaceuticals
- Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases — Roswell Park Cancer Institute
- Study on Combination Immunotherapies for Patients Previously Treated with Immune Checkpoint Inhibitors — ImmunityBio, Inc.
- Study on Regorafenib and Lorigerlimab (RELO Regimen) for High-Risk Colorectal Cancer Patients with Hidden Residual Disease After Standard Treatment — M.D. Anderson Cancer Center
- Study on the Safety and Effectiveness of NEO212 for Patients with Certain Brain Tumors or Brain Metastasis — Neonc Technologies, Inc.
- Study on SAMe Supplementation to Prevent Liver Injury from Oxaliplatin in Colorectal Cancer Patients — Cedars-Sinai Medical Center
- Study on Stereotactic Brain Radiation with or without AGuIX Gadolinium-Based Nanoparticles for Brain Metastases — Dana-Farber Cancer Institute
- Study of AZD5305 Alone and with Other Cancer Treatments in Patients with Advanced Solid Tumors — AstraZeneca
- Study of BDC-3042 Alone and with Cemiplimab in Patients with Advanced Cancers — Bolt Biotherapeutics, Inc.
- Study on CBX-12 for Patients with Advanced or Metastatic Solid Tumors — Cybrexa Therapeutics
- Study on IDE196 for Patients with Solid Tumors with GNAQ/11 Mutations or PRKC Fusions — IDEAYA Biosciences
- Study on Intravenous and Abdominal Paclitaxel and Oral Nilotinib for Abdominal Cancer Spread from Various Primary Cancers — National Cancer Institute (NCI)
- Study on NGM707 Alone and with Pembrolizumab for Advanced or Metastatic Solid Tumors — NGM Biopharmaceuticals, Inc
- Study on RAS(ON) Inhibitors for Patients with Gastrointestinal Solid Tumors — Revolution Medicines, Inc.
- Study of TAS-102 and Radiation Therapy for Treating Liver Metastases from Colorectal Cancer — Massachusetts General Hospital
- Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas — Immunitas Therapeutics
- Study on TU2218 and Pembrolizumab Combination for Advanced Solid Tumors — TiumBio Co., Ltd.
- Study on PC14586 for Patients with Advanced Solid Tumors with a TP53 Y220C Mutation (PYNNACLE) — PMV Pharmaceuticals, Inc
- Study on Tislelizumab for People with Colorectal Cancer in Nigeria — Memorial Sloan Kettering Cancer Center
- Study on Tovorafenib (DAY101) Alone or with Other Treatments for Melanoma and Other Solid Tumors — Day One Biopharmaceuticals, Inc.
- Study on AMB-05X for Patients with ctDNA Positive Colorectal Cancer After Treatment Aimed at Cure — M.D. Anderson Cancer Center
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Colorectal Cancer to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.